Krystal Biotech, Inc. Common Stock KRYS

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

• GlobeNewswire Inc. 3 sept

  Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

  Krystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will participate in a fireside chat at 3:55 pm ET and host investor meetings. The company reported strong Q2 2026 results with $119.2 million in VYJUVEK global revenue and $965.9 million in cumulative revenue since launch, with plans for European expansions and multiple clinical data readouts expected in the second half of 2026.

  

• Zacks Investment Research 2 sept

  Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

  Krystal Biotech shares have gained 12% since its last earnings report, outperforming the S&P 500. The company beat Q2 2026 earnings estimates with EPS of $1.79 vs. consensus of $1.70, and revenues of $119.2 million from Vyjuvek sales grew 24% year-over-year. Despite upward estimate revisions, the stock holds a Zacks Rank #3 (Hold) with an overall VGM Score of D, suggesting in-line returns ahead.

  

• GlobeNewswire Inc. 23 jul

  Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

  Krystal Biotech announced it will report its second quarter 2026 financial results on August 3, 2026, with a conference call and webcast at 8:30 am ET. The company is a commercial-stage biotechnology firm focused on genetic medicines, with VYJUVEK® as its first commercial product—the first redosable gene therapy approved in the United States, Europe, and Japan for treating dystrophic epidermolysis bullosa.

  

• The Motley Fool 21 jul

  Why Tutor Perini Stock Trounced the Market on Tuesday

  Tutor Perini stock surged nearly 8% on Tuesday following news that it will be added to the S&P SmallCap 600 index. The construction company replaces Krystal Biotech in the index, which is itself moving up to the S&P MidCap 400 to fill the vacancy left by Taylor Morrison Home's acquisition by Berkshire Hathaway. The gain is primarily attributed to the 'index effect,' where index funds automatically purchase newly added constituents, though this has little impact on the company's fundamentals.

  

• The Motley Fool 7 jul

  3 Soaring Stocks That May Have More Upside Ahead

  The article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant market expansion opportunities. Marvell Technology is capitalizing on AI infrastructure spending demand for custom chips as an alternative to Nvidia's GPUs.